Psychedelic-Assisted Therapies

Between 1957 and 1967, Argentina experienced a brief yet profound intersection of psychoanalysis and psychedelics, with thousands of therapeutic sessions conducted through the controlled use of LSD and other substances. These treatments, led by pioneering psychotherapists like Dr. Alberto Fontana...

The recent rejection by the Food and Drug Administration (FDA) of an application that would have authorized the use of MDMA for the treatment of post-traumatic stress disorder (PTSD) reignited the already ongoing discussion on psychedelic-assisted therapies. This not only affects the 13 million...

In an engaging episode of Benzinga’s Cannabis Insider podcast, hosts Patricio Liddle and Nicolás Rodríguez welcomed Cody Shandraw, president of Healing Realty Trust, to discuss the role of real estate in the burgeoning sector of psychedelic therapies. Shandraw, who spearheads the strategic...

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024. See previous edition Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More Research Psilocybin for dementia prevention? The potential...

Psychedelics healthcare company Numinus Wellness (OTCQX:NUMIF) shared its unaudited, condensed and consolidated interim financial results for the three and six months ended February 29, 2024.  Q2 showed: Cash position of $4.8 (CA$6.6) million by February 29, 2024, compared to the $14.33...

Canadian licensed psychedelics pharmaceutical manufacturer Optimi Health Corp. (OTCQX:OPTHF) has signed an international agreement to supply natural psilocybin to New Zealand-based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.  The agreement marks Optimi’s first...

State-level psychedelics policy reform keeps moving forward throughout the U.S. Below is a recap of the moves that took place in the past three weeks (see the previous recap.) Missouri: Controversial budget proposal HB 2010 received final approval by the state's House on April 5, a day after it...

Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items from the last two weeks of March 2024. See previous edition Psychedelics Headlines: Substitution Survey, Frank Herbert’s Magic Mushrooms, Celestial Plans And News Review Research Psychedelic...

Clinical-stage psychedelics biotech Atai Life Sciences (NASDAQ:ATAI) announced its consolidated financial results for the fourth quarter and full year 2023. The Numbers: Cash, cash equivalents and short-term investments of $154.2 million by December 31, 2023, as compared to $273.1 million by...

Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a study of Beckley's novel formulation of 5-MeO-DMT in Treatment Resistant Depression (TRD.)  See: Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics...

Welcome to a new episode of the Benzinga Psychedelics Podcast where we’re joined by Robert Barrow, CEO of Mind Medicine (MindMed) (NASDAQ:MNMD), which has taken the development of LSD-based therapy to new heights. The biopharma company recently obtained a "breakthrough therapy" designation...

FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement Clinical-stage psychedelics biopharma company Cybin Inc. (NYSE:CYBN) announced that the Food and Drug Administration has granted...

State-level psychedelics policy reform keeps moving forward throughout the U.S. Below is a recap of the moves that took place in the first two weeks of March (see the previous recap.) Also Read: Indiana Governor Signs Health Bill Including State Funds For Psilocybin Research Maryland: On March 15...

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items concerning the first two weeks of March 2024. See previous edition Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More. Research The...

Clinical-stage neuroscience company Gilgamesh Pharmaceuticals has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, a novel, reportedly cardiac-safe ibogaine analog for the treatment of substance use disorders.  As recently...